Linking GPCR organization states with functional heterogeneity in the pancreatic islet
Lead Research Organisation:
University of Oxford
Department Name: RDM OCDEM
Abstract
The current view of tissue complexity is mainly based upon single-cell screening technologies, which classify cells according to shared traits, such as maturity, proliferative capacity and mutational potential. Often, inferences about cell function are based upon measurements made outside of the tissue context, as well as the characteristics of the state to which the cell belongs. Thus, immature cells tend to be considered as proliferative, but poorly functional, whereas more mature cells are long-lived and highly functional. While single-cell screening approaches are high-dimensional, they do not have the spatiotemporal resolution inherent to light microscopy. The present proposal will leverage recent advances in genome editing, protein labelling, super-resolution imaging and spatial transcriptomics to provide a higher-order in situ organization of cell heterogeneity at the tissue level, with repercussions for our understanding of tissue (dys)function. Using pancreatic islets as an exemplar micro-organ, and GPCRs as candidate cell surface signalling proteins, we will: 1) map GPCR organization/dynamics at the cell population level and integrate this information with underlying transcriptomic features, before re-classifying cell states; 2) understand how higher-order GPCR organization/dynamics change during cell stimulation, metabolic stress and other states of tissue perturbation; 3) functionally interrogate cell states defined by GPCR organization/dynamics using novel activity integrators and cell-specific transcription factor re-expression; and 4) examine higher-order cell heterogeneity across species. The proposed work will show for the first time how the organization and dynamics of individual signalling proteins relate to cell state and cell activity across the cell population. More broadly, these studies will establish a high-resolution view of cell heterogeneity, leading to a step-change in our understanding of the functional organisation of complex tissues.
Publications
Adriaenssens A
(2023)
Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding.
in JCI insight
Ast J
(2023)
Revealing the tissue-level complexity of endogenous glucagon-like peptide-1 receptor expression and signaling.
in Nature communications
Firth G
(2023)
Impact of an SLC30A8 loss-of-function variant on the pancreatic distribution of zinc and manganese: laser ablation-ICP-MS and positron emission tomography studies in mice.
in Frontiers in endocrinology
Galvis D
(2023)
Spatial distribution of heterogeneity as a modulator of collective dynamics in pancreatic beta-cell networks and beyond.
in Frontiers in network physiology
Mendive-Tapia L
(2023)
Acid-Resistant BODIPY Amino Acids for Peptide-Based Fluorescence Imaging of GPR54 Receptors in Pancreatic Islets.
in Angewandte Chemie (International ed. in English)
Mendive-Tapia L
(2023)
Acid-Resistant BODIPY Amino Acids for Peptide-Based Fluorescence Imaging of GPR54 Receptors in Pancreatic Islets
in Angewandte Chemie
Peercy B
(2024)
Synchronizing beta cells in the pancreas
in eLife
Pezhman L
(2023)
PEPITEM modulates leukocyte trafficking to reduce obesity-induced inflammation
in Clinical and Experimental Immunology
Romanò N
(2023)
Median eminence blood flow influences food intake by regulating ghrelin access to the metabolic brain.
in JCI insight
Rückert AK
(2023)
Fine-tuned photochromic sulfonylureas for optical control of beta cell Ca2+ fluxes.
in Diabetic medicine : a journal of the British Diabetic Association
Description | Steve Morgan Foundation-Diabetes UK Grand Challenge |
Amount | £2,546,826 (GBP) |
Funding ID | 23/0006627 |
Organisation | Diabetes UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2024 |
End | 03/2029 |
Title | Chemical probes for the detection and visualization of GIPR |
Description | We developed the GIPR probes and are testing their specificity in pancreatic islets. Our partners (Frank Reimann and Fiona Gribble) are testing the ligands in the brain. We recently filed a European patent to protect intellectual property surrounding these probes, and will look to commercialize going forward. |
Type Of Material | Technology assay or reagent |
Year Produced | 2023 |
Provided To Others? | Yes |
Impact | There is no specific antibody for GIPR, which is holding back understanding of sites of action of this important therapeutic receptor. |
Title | Chemical probes for the detection and visualization of tirzepatide targets (2024) |
Description | Fluorescently labelled tirzepatide to delineate target GLP1R/GIPR binding sites in the periphery and brain, which might underlie effects of the drug on glucose homeostasis and food intake. |
Type Of Material | Technology assay or reagent |
Year Produced | 2023 |
Provided To Others? | No |
Impact | Tirzepatide is a major new drug therapy for type 2 diabetes and obesity. The cells/neurons that tirzepatide binds to exert its biological effects are unknown, in part due to unreliable antibodies for GLP1R/GIPR. Fluorescently-labelled tirzepatide is thus very timely for the field, allowing us to understand how this drug distributes in the body. |
Description | Development and testing of GIPR probes |
Organisation | University of Cambridge |
Department | Institute of Metabolic Science (IMS) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have developed GIPR probes. No antibody exists for this GPCR, which is becoming translationally very relevant, since it is targeted by GLP1R/GIPR dual agonists for the treatment of diabetes and obesity. |
Collaborator Contribution | We developed the GIPR probes and are testing their specificity in pancreatic islets. Our partners (Frank Reimann and Fiona Gribble) are testing the ligands in the brain. We recently filed a European patent to protect intellectual property surrounding these probes, and will look to commercialize going forward. |
Impact | The partnership is still in its early phase, but we have already filed a patent, have a mansucript under revision with Eli Lilly and University Cambridge. The collaboration is multi-disciplinary spanning chemical biology, neuroscience, and involves an industrial partner (Eli Lilly). |
Start Year | 2021 |
Description | Endogenous GPCR clustering analysis |
Organisation | University of Birmingham |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We collaborated with Prof Dylan Owen's lab to perform dSTORM microscopy, as well as clustering analysis of the ensuing datasets. |
Collaborator Contribution | Dylan's lab provided free time on an ONI nanoimager system (usually 37 GBP per hr), as well as technical assistance with analysis. |
Impact | We recently published a manuscript together in Nature Communications, which shows data from the collaboration. https://pubmed.ncbi.nlm.nih.gov/36653347/ |
Start Year | 2021 |
Description | Optimization of methods to purify stem cell-derived beta cells |
Organisation | Novo Nordisk |
Department | Novo Nordisk Research Centre Oxford |
Country | United Kingdom |
Sector | Private |
PI Contribution | We discovered that only ~ 50% of stem cell-derived beta cells (SBC) express GLP1R, a mature functional marker. Using our proprietary technology (GLP1R chemical probes), we have devised steps to increase mature SBC yield by sorting according to GLP1R positivity. |
Collaborator Contribution | Novo Nordisk Research Centre Oxford funded a postdoctoral researcher to conduct the research. They also provide access to their facility, including provision of reagent for production and screening of SBCs. |
Impact | N/A |
Start Year | 2023 |
Description | Diabetes UK supporter visit |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Diabetes UK site visit for their South East supporter group, including individuals with lived experience. Visitors were provided with an overview of MRC-funded activities, as well as provided with a tour of OCDEM clinical research unit, islet transplantation and research facilities, including hands-on demos. |
Year(s) Of Engagement Activity | 2023 |
Description | Oxford Science and Ideas Festival |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The lab participated in the Oxford Science Festival, on behalf of the Radcliffe Department of Medicine. We set up a stall with hands-on demo relevant to diabetes/obesity. |
Year(s) Of Engagement Activity | 2023 |
URL | https://if-oxford.com/events/ |